Veradermics MANE Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $20.93M— | —— | —— | —— | $11.45M+96.7% | ||
| $8.94M— | —— | —— | —— | $1.47M+68.0% | ||
| $29.86M— | —— | —— | —— | $12.92M+92.9% | ||
| -$29.86M— | —— | —— | —— | -$12.92M-92.9% | ||
| —— | $0— | $0— | $0— | $0-100% | ||
| $2.63M— | —— | —— | —— | $515K+610% | ||
| -$27.23M— | —— | —— | —— | -$12.4M-87.3% | ||
| $0— | —— | —— | —— | $0— | ||
| -$27.23M— | —— | —— | —— | -$12.4M-87.3% | ||
| -$1.32— | —— | —— | —— | -$19.79-114% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Veradermics profitable?
- Veradermics is not currently profitable: it reported a net loss of $52.9M over the trailing twelve months.
- What is Veradermics 's earnings per share?
- Veradermics 's diluted EPS over the trailing twelve months is $-39.63.
- Where does Veradermics 's income statement data come from?
- Every line is extracted from Veradermics 's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.